The treatment of malignant meningioma with verotoxin
| Autor: | Anita Nutikka, Clifford A. Lingwood, Wouter R. van Furth, James T. Rutka, Bodour Salhia |
|---|---|
| Přispěvatelé: | Neurosurgery |
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty Malignant meningioma IOMM-Lee Biology lcsh:RC254-282 meningioma Meningioma 03 medical and health sciences 0302 clinical medicine Glycolipid medicine Meningeal Neoplasm apoptosis microvascular density lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease In vitro 3. Good health verotoxin Cell culture Apoptosis 030220 oncology & carcinogenesis Benign Meningioma 030217 neurology & neurosurgery |
| Zdroj: | Neoplasia (New York, N.Y.), 4(4), 304-311. Elsevier Inc. Neoplasia: An International Journal for Oncology Research, Vol 4, Iss 4, Pp 304-311 (2002) |
| ISSN: | 1522-8002 |
| DOI: | 10.1038/sj.neo.7900243 |
| Popis: | Malignant meningiomas (MMs) are aggressive intracranial neoplasms with a 75% 5-year recurrence rate. Verotoxin 1 (VTi) is an Escherichia coli toxin, which has recently been shown to have anti-neoplastic action by targeting the globotriosylceramide (Gb3) glycolipid on tumor cells and tumor neovasculature. To investigate the potential use of VTi as a clinical agent for MM, we initially tested 16 meningiomas for Gb3 expression. Nine of 11 MMs (82%), but only one of five benign meningiomas (20%), were positive for Gb3. An orthotopic xenograft model was used to test the efficacy of VTi treatment for MM. We first demonstrated that Gb3 was highly expressed by the MM cell line, IOMM-Lee, and that this cell line was highly sensitive to VTi treatment in vitro. A single intratumoral injection of VTi significantly improved survival in nude mice harboring intracranial tumours (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|